1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neuropharmacology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neuropharmacology Market, by Drug Class
8.1.1. Antidepressants
8.1.1.1. Market Revenue and Forecast
8.1.2. Antipsychotics
8.1.2.1. Market Revenue and Forecast
8.1.3. Antiepileptics
8.1.3.1. Market Revenue and Forecast
8.1.4. Anti-Parkinson Drugs
8.1.4.1. Market Revenue and Forecast
8.1.5. Alzheimer's Disease Drugs
8.1.5.1. Market Revenue and Forecast
8.1.6. CNS Stimulants
8.1.6.1. Market Revenue and Forecast
9.1. Neuropharmacology Market, by Indication
9.1.1. Depression
9.1.1.1. Market Revenue and Forecast
9.1.2. Schizophrenia
9.1.2.1. Market Revenue and Forecast
9.1.3. Parkinson's Disease
9.1.3.1. Market Revenue and Forecast
9.1.4. Alzheimer's Disease
9.1.4.1. Market Revenue and Forecast
9.1.5. Attention Deficit Hyperactivity Disorder (ADHD)
9.1.5.1. Market Revenue and Forecast
10.1. Neuropharmacology Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast
10.1.3. Transdermal
10.1.3.1. Market Revenue and Forecast
10.1.4. Transdermal
10.1.4.1. Market Revenue and Forecast
11.1. Neuropharmacology Market, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast
12.1. Neuropharmacology Market, by End User
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Neurology Clinics
12.1.2.1. Market Revenue and Forecast
12.1.3. Ambulatory Care Centers
12.1.3.1. Market Revenue and Forecast
12.1.4. Homecare Settings
12.1.4.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class
13.1.2. Market Revenue and Forecast, by Indication
13.1.3. Market Revenue and Forecast, by Route of Administration
13.1.4. Market Revenue and Forecast, by Distribution Channel
13.1.5. Market Revenue and Forecast, by End User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class
13.1.6.2. Market Revenue and Forecast, by Indication
13.1.6.3. Market Revenue and Forecast, by Route of Administration
13.1.6.4. Market Revenue and Forecast, by Distribution Channel
13.1.6.5. Market Revenue and Forecast, by End User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Class
13.1.7.2. Market Revenue and Forecast, by Indication
13.1.7.3. Market Revenue and Forecast, by Route of Administration
13.1.7.4. Market Revenue and Forecast, by Distribution Channel
13.1.7.5. Market Revenue and Forecast, by End User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class
13.2.2. Market Revenue and Forecast, by Indication
13.2.3. Market Revenue and Forecast, by Route of Administration
13.2.4. Market Revenue and Forecast, by Distribution Channel
13.2.5. Market Revenue and Forecast, by End User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class
13.2.6.2. Market Revenue and Forecast, by Indication
13.2.6.3. Market Revenue and Forecast, by Route of Administration
13.2.7. Market Revenue and Forecast, by Distribution Channel
13.2.8. Market Revenue and Forecast, by End User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Drug Class
13.2.9.2. Market Revenue and Forecast, by Indication
13.2.9.3. Market Revenue and Forecast, by Route of Administration
13.2.10. Market Revenue and Forecast, by Distribution Channel
13.2.11. Market Revenue and Forecast, by End User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Drug Class
13.2.12.2. Market Revenue and Forecast, by Indication
13.2.12.3. Market Revenue and Forecast, by Route of Administration
13.2.12.4. Market Revenue and Forecast, by Distribution Channel
13.2.13. Market Revenue and Forecast, by End User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Drug Class
13.2.14.2. Market Revenue and Forecast, by Indication
13.2.14.3. Market Revenue and Forecast, by Route of Administration
13.2.14.4. Market Revenue and Forecast, by Distribution Channel
13.2.15. Market Revenue and Forecast, by End User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class
13.3.2. Market Revenue and Forecast, by Indication
13.3.3. Market Revenue and Forecast, by Route of Administration
13.3.4. Market Revenue and Forecast, by Distribution Channel
13.3.5. Market Revenue and Forecast, by End User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class
13.3.6.2. Market Revenue and Forecast, by Indication
13.3.6.3. Market Revenue and Forecast, by Route of Administration
13.3.6.4. Market Revenue and Forecast, by Distribution Channel
13.3.7. Market Revenue and Forecast, by End User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Drug Class
13.3.8.2. Market Revenue and Forecast, by Indication
13.3.8.3. Market Revenue and Forecast, by Route of Administration
13.3.8.4. Market Revenue and Forecast, by Distribution Channel
13.3.9. Market Revenue and Forecast, by End User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Drug Class
13.3.10.2. Market Revenue and Forecast, by Indication
13.3.10.3. Market Revenue and Forecast, by Route of Administration
13.3.10.4. Market Revenue and Forecast, by Distribution Channel
13.3.10.5. Market Revenue and Forecast, by End User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Drug Class
13.3.11.2. Market Revenue and Forecast, by Indication
13.3.11.3. Market Revenue and Forecast, by Route of Administration
13.3.11.4. Market Revenue and Forecast, by Distribution Channel
13.3.11.5. Market Revenue and Forecast, by End User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class
13.4.2. Market Revenue and Forecast, by Indication
13.4.3. Market Revenue and Forecast, by Route of Administration
13.4.4. Market Revenue and Forecast, by Distribution Channel
13.4.5. Market Revenue and Forecast, by End User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class
13.4.6.2. Market Revenue and Forecast, by Indication
13.4.6.3. Market Revenue and Forecast, by Route of Administration
13.4.6.4. Market Revenue and Forecast, by Distribution Channel
13.4.7. Market Revenue and Forecast, by End User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class
13.4.8.2. Market Revenue and Forecast, by Indication
13.4.8.3. Market Revenue and Forecast, by Route of Administration
13.4.8.4. Market Revenue and Forecast, by Distribution Channel
13.4.9. Market Revenue and Forecast, by End User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Drug Class
13.4.10.2. Market Revenue and Forecast, by Indication
13.4.10.3. Market Revenue and Forecast, by Route of Administration
13.4.10.4. Market Revenue and Forecast, by Distribution Channel
13.4.10.5. Market Revenue and Forecast, by End User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Drug Class
13.4.11.2. Market Revenue and Forecast, by Indication
13.4.11.3. Market Revenue and Forecast, by Route of Administration
13.4.11.4. Market Revenue and Forecast, by Distribution Channel
13.4.11.5. Market Revenue and Forecast, by End User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class
13.5.2. Market Revenue and Forecast, by Indication
13.5.3. Market Revenue and Forecast, by Route of Administration
13.5.4. Market Revenue and Forecast, by Distribution Channel
13.5.5. Market Revenue and Forecast, by End User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class
13.5.6.2. Market Revenue and Forecast, by Indication
13.5.6.3. Market Revenue and Forecast, by Route of Administration
13.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.5.7. Market Revenue and Forecast, by End User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Drug Class
13.5.8.2. Market Revenue and Forecast, by Indication
13.5.8.3. Market Revenue and Forecast, by Route of Administration
13.5.8.4. Market Revenue and Forecast, by Distribution Channel
13.5.8.5. Market Revenue and Forecast, by End User
14.1. Pfizer
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Eli Lilly and Company
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Johnson & Johnson
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. AbbVie
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Novartis
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Roche
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Merck & Co.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Bristol Myers Squibb
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Otsuka Pharmaceutical
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Lundbeck
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
